Advanced Filters
noise

pompe-disease Clinical Trials

A listing of pompe-disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 55 clinical trials
A Abigail Browngoehl

A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)

This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of AB-1009 in adult participants with late-onset Pompe disease (LOPD).

18 years of age All Phase 1/2
E Eleanor Rodriguez-Rassi, MPH

Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

This is a longitudinal natural history study of Infantile Pompe disease. The investigators will regularly collect and review medical information regarding the diagnosis of Pompe disease, response to enzyme replacement (ERT) using alglucosidase alfa (Lumizyme/Myozyme) and response to immunosuppressive therapy in cases at risk for developing or those who have …

years of age All Phase N/A
C Cinzia Fattore, MD

Phrenic Nerve and Diaphragm Electrophysiology in Pompe Disease

Pompe disease is traditionally considered a lysosomal myopathy. However, increasing experimental and clinical evidence suggests involvement of the entire motor unit, including motor neurons, peripheral nerves, neuromuscular junctions, and skeletal muscle. Respiratory impairment is a major cause of morbidity and mortality, and diaphragm dysfunction is frequently observed. Clinical observations at …

18 years of age All Phase N/A

Avalglucosidase Alfa Pregnancy Study

This is a worldwide, descriptive safety study collecting data on women and their offspring exposed to avalglucosidase alfa during pregnancy and/or lactation, to assess the risks of avalglucsodiase alfa on pregnancy and maternal complications and adverse effects in the developing fetus, neonate, and infant. Outcomes in exposed infants, including growth …

years of age Female Phase N/A
G GIULIANI ALEXANDRA

Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases

Since 2017, more than 250 analyses performed at the Molecular Genetics Laboratory of the Timone Enfant Hospital have yielded negative results in patients with rare genetic muscle diseases. The researchers hypothesise that some of these misdiagnosed patients carry pathogenic RNA (transcript) disrupting variants that were not identified by DNA sequencing. …

years of age All Phase N/A
A Arooj Agha

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease

The group used a randomized controlled trial to conduct a post-marketing re-evaluation study of Wangbi granules. The study was conducted to observe the degree of clinical remission in rheumatoid arthritis patients with low disease activity after standard methotrexate and tofacitinib citrate treatment, using a combination of Chinese and Western medicine …

18 - 75 years of age All Phase 1
D Denzil Romfh, OD

OCT Angiography in Wet AMD

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) evaluate patients undergoing treatment for wet AMD determine if reduced flow to the choroid is a risk factor for …

50 - 100 years of age All Phase N/A
C Ciro Costagliola, Director Of Ophthalmology Unit

Lutein by Scleral Iontophoresis in AMD

The objective of the clinical investigation is to evaluate the performance, safety and degree of tolerability resulting from the use of the iontophoresis medical device in adult subjects diagnosed with AMD stage 3 (AREDS classification) in one or both eyes.

55 - 100 years of age All Phase N/A
C Christine A Sinkey, BSN, CCRC

MMP-9 Inhibition for Recalcitrant Wet AMD

Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 …

50 - 99 years of age All Phase 2

Gene Therapy(FT-003) for Wet AMD

The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of disposable vitreous injection of FT-003 in subjects with neovascular age-related Macular Degeneration (nAMD). The study was divided into two phases, Phase 1 dose escalation and Phase II dose expansion.

50 - 80 years of age All Phase 1/2

Simplify language using AI